CBS 2019
CBSMD教育中心
中 文

推荐文献

Abstract

Recommended Article

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial Current Perspectives on Coronavirus Disease 2019 and Cardiovascular Disease: A White Paper by the JAHA Editors Coronary Artery Calcium Is Associated with Left Ventricular Diastolic Function Independent of Myocardial Ischemia Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk Percutaneous Coronary Intervention Readmissions Where Are the Solutions? Disrupting Fellow Education Through Group Texting: WhatsApp in Fellow Education?

Clinical Trial2018 Oct 27. [Epub ahead of print]

JOURNAL:J Am Coll Cardiol. Article Link

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial

M Szarek, HD White, PH Steg, ODYSSEY OUTCOMES Committees and Investigators. Keywords: Alirocumab; acute coronary syndrome; total events

FuLL TEXT PDF